Table 2.
Efficacy of approved checkpoint blockade agents in relationship with PD-L1 status
| Drug | Target | Disease | Study | Patients (n) |
Outcome affected by PD-L1 status |
Reference |
|---|---|---|---|---|---|---|
| Atezolizumab | PD-L1 | Previously treated metastatic NSCLC | POPLAR | 142 | Yes (PD-L1+ ≥ 1%) | [27] |
| Atezolizumab | PD-L1 | Previously treated metastatic NSCLC | OAK | 241 | No | [28] |
| Avelumab | PD-L1 | Platinum-refractory locally advanced or metastatic urothelial carcinoma | JAVELIN | 161 | No | [29] |
| Durvalumab | PD-L1 | Locally advanced, unresectable NSCLC | PACIFIC | 473 | No | [30] |
| Durvalumab | PD-L1 | Platinum-refractory locally advanced or metastatic urothelial carcinoma | 1108 | 191 | Yes (PD-L1 + ≥25%) | [31] |
| Nivolumab | PD-1 | Platinum-refractory metastatic squamous NSCLC | CheckMate 017 | 292 | No | [32] |
| Nivolumab | PD-1 | Locally advanced or metastatic urothelial carcinoma | CheckMate 275 | 270 | Yes (PD-L1 + ≥ 1%) | [33] |
| Nivolumab | PD-1 | Chemotherapy resistant MSI-high metastatic colorectal cancer | CheckMate 142 | 74 | No | [34] |
| Nivolumab | PD-1 | Relapsed/refractory classic HL | CheckMate 205 | 97 | Yes | [35] |
| Nivolumab+ipilimumab | PD-1+CTLA-4 | BRAFV600-WT unresectable or metastatic melanoma | CheckMate 069 | 142 | No | [36] |
| Nivolumab ± ipilimumab | PD-1+CTLA-4 | Previously untreated advanced melanoma | CheckMate 067 | 630 | No | [37••] |
| Pembrolizumab | PD-1 | Previously treated or treatment-naive advanced or metastatic NSCLC | KEYNOTE-001 | 495 | Yes (PD-L1+ ≥ 50%) | [38] |